Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
作者： Richard R. Furman , Morton Coleman , Daniel Muss , John P. Leonard
DOI: 10.1007/978-0-387-29346-2_7
关键词:
摘要: Non-Hodgkin’s lymphomas are a heterogeneous group of malignancies that result from the clonal expansion mature lymphocytes unable to terminally differentiate. Each lymphoma is derived lymphocyte frozen at particular stage development and often retains many immunophenotypic, morphologic, molecular markers corresponding stage. Thus, well marked by expression series differentiation antigens, termed “cluster differentiation” (CD) antigens. These characteristics serve as basis for World Health Organization (WHO) Classification Lymphoid Neoplasms [1]. proteins also valuable diagnosing classifying lymphomas, reliable targets therapy.
springer.com
sci-hub.st 参考文章(90)
V. Diehl, A. Lister, J.A. Radford, D. Ma, P. Johnson, A. Engert, F. Reyes, C. Haioun, H. Tilly, R. Capdeville, B. Coiffier, N. Ketterer, M. Feuring Buske, Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study Blood. ,vol. 92, pp. 1927- 1932 ,(1998) , 10.1182/BLOOD.V92.6.1927
Josée Golay, Luisella Zaffaroni, Thomas Vaccari, Manuela Lazzari, Gian-Maria Borleri, Sergio Bernasconi, Francesco Tedesco, Alessandro Rambaldi, Martino Introna, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood. ,vol. 95, pp. 3900- 3908 ,(2000) , 10.1182/BLOOD.V95.12.3900
Neutropenia in patients treated with rituximab. The New England Journal of Medicine. ,vol. 348, pp. 2691- 2694 ,(2003) , 10.1056/NEJM200306263482620
ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna, DR Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood. ,vol. 83, pp. 435- 445 ,(1994) , 10.1182/BLOOD.V83.2.435.435
A. Melnyk, A. Rodriguez, W.C. Pugh, F. Cabannillas, Evaluation of the Revised European-American Lymphoma Classification Confirms the Clinical Relevance of Immunophenotype in 560 Cases of Aggressive Non-Hodgkin's Lymphoma Blood. ,vol. 89, pp. 4514- 4520 ,(1997) , 10.1182/BLOOD.V89.12.4514
MJ Dyer, G Hale, FG Hayhoe, H Waldmann, Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. ,vol. 73, pp. 1431- 1439 ,(1989) , 10.1182/BLOOD.V73.6.1431.1431
OW Press, F Appelbaum, JA Ledbetter, PJ Martin, J Zarling, P Kidd, ED Thomas, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas Blood. ,vol. 69, pp. 584- 591 ,(1987) , 10.1182/BLOOD.V69.2.584.584
KC Anderson, MP Bates, BL Slaughenhoupt, GS Pinkus, SF Schlossman, LM Nadler, Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation Blood. ,vol. 63, pp. 1424- 1433 ,(1984) , 10.1182/BLOOD.V63.6.1424.1424
David G. Maloney, Antonio J. Grillo-López, Christine A. White, David Bodkin, Russell J. Schilder, James A. Neidhart, Nalini Janakiraman, Kenneth A. Foon, Tina-Marie Liles, Brian K. Dallaire, Ken Wey, Ivor Royston, Thomas Davis, Ronald Levy, IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Blood. ,vol. 90, pp. 2188- 2195 ,(1997) , 10.1182/BLOOD.V90.6.2188
H. Pels, H. Schulz, O. Manzke, E. Hom, A. Thall, A. Engert, Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. Journal of Neuro-oncology. ,vol. 59, pp. 213- 216 ,(2002) , 10.1023/A:1019999830455